- October 3, 2026
If you are considering semaglutide for weight loss, you may be wondering: Can you get Ozempic or semaglutide on the NHS in 2026? The answer is potentially yes, but there is an important distinction between Ozempic and Wegovy, and NHS access depends on your medical circumstances, BMI, weight-related health conditions and where you live.
Semaglutide is the active ingredient used in several medicines. Wegovy is licensed for weight management, while Ozempic is primarily used to manage type 2 diabetes. The NHS states that semaglutide is prescription-only and may be available through NHS or private services depending on why it is being prescribed.
For people seeking semaglutide specifically for weight management in England, treatment is generally provided through a specialist weight management service and is subject to eligibility criteria.
This guide explains the 2026 NHS semaglutide eligibility criteria, BMI requirements, how to apply, what happens during assessment, possible alternatives and important safety considerations.
Medical disclaimer: This article is for general health information and does not replace advice from a GP, pharmacist or specialist weight-management clinician. NHS prescribing arrangements can vary by UK nation and local NHS organisation.
Semaglutide is a medicine from a group called GLP-1 receptor agonists. For weight management, it can reduce appetite and increase feelings of fullness, helping some people reduce their food intake alongside dietary and physical-activity changes.
Semaglutide is available under different brand names for different medical purposes:
Therefore, if you are searching for “Ozempic on the NHS for weight loss”, it is important to understand that NHS weight-management treatment with semaglutide generally refers to Wegovy, rather than using Ozempic simply as a weight-loss medicine.
If you are exploring your weight and health risks before considering medication, our guide to BMI, weight categories and what the NHS says in 2026 can provide useful background.
Yes, some people can receive semaglutide through the NHS for weight management in 2026, but it is not available to everyone who wants to lose weight.
NHS England states that semaglutide (Wegovy) for obesity is prescribed through a specialist weight management service. Your clinician will consider your BMI, weight-related health conditions and whether the treatment is appropriate for you.
NICE guidance sets eligibility around:
Meeting a BMI threshold does not automatically guarantee a prescription. A healthcare professional needs to assess whether semaglutide is clinically suitable.
This is one of the most common points of confusion.
Ozempic contains semaglutide, but it is primarily a type 2 diabetes medicine. Wegovy is the semaglutide brand used for weight management.
The NHS describes semaglutide as being available under the brands Wegovy, Ozempic and Rybelsus, with Wegovy used for obesity and Ozempic/Rybelsus used for type 2 diabetes.
So, if your goal is weight loss rather than diabetes management, you should generally discuss NHS weight-management treatment and Wegovy with your GP or specialist service rather than asking specifically for Ozempic.
Eligibility depends on the specific NHS pathway and your clinical circumstances.
For semaglutide used for weight management, NICE’s criteria include an initial BMI of:
For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, lower BMI thresholds are generally used.
Depending on your circumstances, examples can include conditions associated with excess weight such as:
Your healthcare team will assess your overall health rather than relying on BMI alone.
For example, the NHS explains that obesity can be associated with conditions including type 2 diabetes, cardiovascular disease and high blood pressure.
BMI is one of the measurements used to assess whether someone is overweight or living with obesity.
For most adults:
However, BMI has limitations. It cannot distinguish between muscle and fat and may not accurately reflect health risk for every individual. The NHS also uses lower BMI thresholds for some ethnic groups because of increased risk of weight-related health problems at lower BMI levels.
This is why a clinician may consider other factors such as your waist measurement, medical history, medications, blood pressure, blood tests and existing health conditions.
Your medical history can be particularly important when considering semaglutide.
A GP or specialist may consider whether you have conditions such as:
Your current medicines are also important. Some medicines can affect weight, while semaglutide can interact with or affect the management of certain other medicines.
The NHS specifically advises patients to tell their doctor or pharmacist about medicines including insulin, some diabetes medicines, levothyroxine and warfarin before using semaglutide.
There is not a simple NHS form that guarantees access to semaglutide.
Instead, the usual process involves assessment by an appropriate NHS healthcare professional and, where required, referral to a specialist weight management service.
Start by discussing your weight, BMI, health conditions and previous attempts at weight management.
Your GP may:
Some local NHS services may also allow people to self-refer for weight-management support. The NHS recommends checking your GP surgery, local integrated care board or NHS weight-management services to see what is available locally.
If you appear to meet the criteria, you may be referred to a specialist weight management service.
The assessment may look at:
Semaglutide is not automatically the first or only option.
Your clinician may discuss:
The NHS states that weight-loss medicines are generally used alongside diet and lifestyle advice rather than as a replacement for healthy eating and physical activity.
If semaglutide is considered suitable, your healthcare professional will explain how to use it and discuss potential benefits, limitations and side effects.
For weight management, semaglutide is given as a once-weekly injection.
NICE guidance has specific restrictions around semaglutide for weight management, including use within a specialist weight-management service and a maximum treatment period specified in the current recommendation.
Your clinician will monitor your response and decide whether continuing treatment remains appropriate.
NICE guidance also says that stopping semaglutide should be considered if a person has not lost at least 5% of their initial body weight after 6 months of treatment.
Treatment decisions should therefore be based on clinical response rather than simply continuing the medicine indefinitely.
This is important because “NHS” does not mean exactly the same prescribing pathway across England, Scotland, Wales and Northern Ireland.
The eligibility information discussed above is primarily based on NHS England and NICE guidance.
Even within England, local integrated care boards may have different arrangements for accessing weight-management services and implementing treatment pathways. NHS England specifically advises checking with your local ICB regarding eligibility for assessment.
Therefore, if you live outside England, check the relevant NHS service in your nation rather than assuming the English pathway automatically applies.
Having a BMI below the relevant threshold does not mean you cannot receive help with weight management.
The NHS provides lifestyle and weight-management support, and some local services allow people to self-refer.
Depending on your circumstances, your healthcare professional may recommend:
It is also important not to assume that a weight-loss injection is necessarily the best option simply because your BMI falls within a particular range.
Semaglutide can also be prescribed for type 2 diabetes, but the prescribing criteria and purpose of treatment are different from its use for obesity.
Ozempic and Rybelsus are associated with type 2 diabetes treatment, while Wegovy is used for weight management.
If you have diabetes and are considering semaglutide, your GP, diabetes team or prescribing clinician should determine which treatment is appropriate based on your blood glucose control, other medicines and overall health.
You can also read our guide to diabetes diet plans and foods to eat and avoid for additional information about lifestyle management.
The role of semaglutide in people with cardiovascular disease has also expanded.
In April 2026, NHS England announced that Wegovy was being made available for eligible people with cardiovascular disease who are overweight, following NICE approval. The announced group includes people who have previously experienced a heart attack, stroke or peripheral arterial disease and have a BMI of at least 27.
This is an important development because it means semaglutide eligibility is not simply about wanting to lose weight.
Your existing cardiovascular risk and medical history can affect whether treatment is appropriate.
Semaglutide can also be prescribed privately if a qualified healthcare professional considers it appropriate.
However, private prescribing does not mean the medicine is automatically suitable or risk-free.
The NHS advises people purchasing private Wegovy to use a registered pharmacy, because counterfeit weight-loss medicines are a potential risk.
If you are considering private treatment, make sure the provider performs a proper clinical assessment rather than simply selling medication based on a questionnaire.
Semaglutide acts on GLP-1 receptors.
For weight management, its effects can include:
The NHS explains that semaglutide can help people lose weight when combined with dietary changes and physical activity.
It should therefore be viewed as one part of a broader weight-management programme, not as a replacement for healthy lifestyle changes.
Semaglutide can cause side effects, particularly gastrointestinal symptoms.
Possible side effects include:
Your doctor or pharmacist should explain the potential side effects before treatment.
Semaglutide is not suitable for everyone. The NHS advises that it may not be appropriate for people with certain medical conditions, including some people who have had pancreatitis or an allergic reaction to semaglutide or another GLP-1 agonist.
Semaglutide should not be used during pregnancy.
The NHS advises that semaglutide is not used during pregnancy because there is insufficient information about its safety for an unborn baby. If you are planning to become pregnant, the NHS advises stopping semaglutide at least 2 months before trying to conceive.
It is also not used while breastfeeding according to current NHS information.
If you are pregnant, breastfeeding or planning a pregnancy, speak to your healthcare professional before starting or continuing any weight-loss medicine.
Before treatment, tell your clinician about:
The NHS specifically advises people taking semaglutide to tell healthcare professionals before surgery or procedures requiring anaesthesia or sedation.
Weight management is usually a long-term process.
Semaglutide can help reduce appetite while it is being taken, but stopping treatment does not permanently remove the biological and behavioural factors that influence body weight.
This is why NHS weight-management services emphasise lifestyle and behavioural support alongside medication.
If treatment is stopped, your healthcare professional can help you plan how to maintain healthy eating, physical activity and other weight-management habits.
Semaglutide is not the only medicine used in NHS weight management.
Other options can include medicines such as:
The appropriate medicine depends on your medical history, BMI, health conditions and the NHS pathway available to you.
Tirzepatide has become particularly important in the NHS weight-management pathway. NHS England describes a phased implementation approach, with initial access prioritised for people with the highest clinical need.
For more information about NHS weight-loss injections, you can also read our existing guide on how to get weight-loss injections on the NHS.
You can also read our detailed Ozempic UK guide covering how it works, cost and NHS eligibility.
No.
Both medicines affect appetite and can support weight loss, but they work differently.
Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide acts on both GIP and GLP-1 receptors. NHS information explains that tirzepatide can reduce appetite and increase feelings of fullness through its dual action.
Your clinician can determine which treatment, if any, is appropriate for you.
Medication is not the only way to improve your health or manage your weight.
The NHS recommends a combination of dietary changes, physical activity and appropriate support.
If you are unsure how much food you need each day, our guide on how many calories you should eat to lose weight may help you understand the basic principles.
However, calorie requirements vary considerably between individuals. Avoid extremely restrictive diets, particularly if you have diabetes, an eating disorder, are pregnant or have another medical condition requiring dietary management.
Sometimes difficulty losing weight is not simply a matter of food intake or physical activity.
The NHS notes that certain health conditions and medicines can make maintaining a healthy weight more difficult. Examples include some endocrine conditions, depression, certain medicines and menopause or perimenopause.
If your weight has changed unexpectedly or you have other symptoms, speak to your GP rather than assuming you simply need a stronger weight-loss medicine.
You can discuss weight-management treatment with your GP, but Ozempic is primarily associated with type 2 diabetes. For obesity and weight management, Wegovy is the semaglutide brand used for this indication.
If you meet the relevant NHS criteria and treatment is prescribed through an NHS service, you do not normally pay a private prescription price for the medicine. However, eligibility and access depend on the NHS pathway and your location.
Current NICE criteria include a BMI of 35 kg/m² or above with at least one weight-related comorbidity, or BMI 30–34.9 kg/m² with a qualifying weight-related condition and criteria for specialist-service referral. Lower BMI thresholds generally apply to certain ethnic groups.
Some NHS weight-management services allow self-referral, but access varies locally. The NHS recommends checking your GP surgery, local ICB or NHS weight-management services for available options.
They contain the same active ingredient, semaglutide, but they are different branded medicines with different licensed uses. Wegovy is used for weight management, while Ozempic is primarily used for type 2 diabetes.
Semaglutide is used for type 2 diabetes, but the appropriate product, dose and treatment plan depend on your individual circumstances. Your diabetes team or GP should advise you.
Private semaglutide treatment is available through legitimate healthcare providers, but you should only obtain prescription medicines from appropriately regulated providers and pharmacies. The NHS warns about counterfeit weight-loss medicines sold online.
No. BMI is only one part of the assessment. A clinician must determine whether you meet the relevant criteria and whether semaglutide is clinically suitable.
If you want to discuss semaglutide with your GP or NHS weight-management service, prepare useful information before your appointment.
Consider recording:
This gives your healthcare professional a clearer picture of your situation and can help determine which treatment pathway is appropriate.
Yes, semaglutide can be available through the NHS in 2026 for eligible patients, but it is not a general-purpose weight-loss injection available to everyone.
For weight management, the relevant semaglutide brand is generally Wegovy rather than Ozempic. Current NHS England guidance says semaglutide is prescribed through specialist weight-management services, with eligibility based on factors including BMI and weight-related health conditions.
The most practical next step is to speak with your GP or check your local NHS weight-management service. You may be assessed for semaglutide or another appropriate treatment, alongside dietary, physical-activity and behavioural support.
NHS access can change as national guidance and local services develop, so always confirm current eligibility with your local NHS service before making treatment decisions.